SKYE
Skye Bioscience, Inc.Company Information
- Company Name
- Skye Bioscience, Inc.
- CIK
- CIK0001516551
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- SKYE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- SKYE
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-03-13
- Last sale
- 2026-09-23
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 231,263
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 16,026,147
- Shares outstanding
- 39,694,243
- Ownership
- 40.37%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -53.69%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Nonrelated Party | - | - | - | - | - | - | 1 | - | - | - | 1 | - | ||||||
| Related Party | - | - | - | - | - | - | 1 | - | - | - | 1 | - | ||||||
Assets Current | ||||||||||||||||||
| Cash | - | - | - | - | - | - | - | - | - | - | 1 | - | ||||||
| Cash And Cash Equivalents At Carrying Value | 8 | 8 | 6 | 18 | 24 | 46 | 68 | 67 | 74 | 83 | 1 | 5 | ||||||
| Short Term Investments | 2 | 9 | 20 | 17 | 25 | 13 | 0 | - | - | - | - | - | ||||||
| Prepaid Expense Current | 0 | 1 | 1 | 4 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | ||||||
| Other Assets Current | 0 | 0 | 1 | 1 | 1 | 3 | 2 | 3 | 3 | 2 | 1 | 1 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | - | - | - | - | - | - | 0 | 9 | 9 | 9 | 9 | 9 | ||||||
| Assets Current | 11 | 19 | 27 | 40 | 51 | 63 | 71 | 80 | 87 | 95 | 12 | 15 | ||||||
| Property Plant And Equipment Net | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 11 | 19 | 28 | 41 | 52 | 65 | 73 | 82 | 87 | 95 | 12 | 16 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 4 | 2 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | - | 2 | ||||||
| Accounts Payable Related Parties Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Employee Related Liabilities Current | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | ||||||
| Interest Payable Current | - | - | - | - | - | - | - | 0 | 0 | 0 | - | - | ||||||
| Other Liabilities Current | 1 | 3 | 3 | 2 | 2 | 1 | 1 | 2 | 1 | 3 | - | 1 | ||||||
| Due To Other Related Parties Classified Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Loss Contingency Accrual Carrying Value Current | 5 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 6 | 6 | 6 | 6 | ||||||
| Loans Payable Current | 0 | 0 | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Long Term Debt Current | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Liabilities Current | 12 | 10 | 8 | 8 | 8 | 5 | 4 | 6 | 14 | 16 | 14 | 14 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Convertible Debt Current | - | - | - | - | - | - | 0 | 0 | 5 | 5 | 4 | 4 | ||||||
| Liabilities | 12 | 10 | 8 | 8 | 8 | 6 | 5 | 6 | 14 | 16 | 14 | 14 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 210 | 208 | 207 | 205 | 203 | 201 | 199 | 197 | 190 | 188 | 102 | 102 | ||||||
| Retained Earnings Accumulated Deficit | -210 | -199 | -187 | -172 | -160 | -142 | -131 | -121 | -117 | -109 | -104 | -100 | ||||||
| Stockholders Equity | -0 | 9 | 20 | 33 | 44 | 59 | 68 | 76 | 73 | 79 | -2 | 2 | ||||||
| Liabilities And Stockholders Equity | 11 | 19 | 28 | 41 | 52 | 65 | 73 | 82 | 87 | 95 | 12 | 16 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 35 | 35 | 33 | 31 | 31 | 31 | 31 | 30 | 28 | 28 | 12 | 12 | ||||||
| Shares Outstanding | 35 | 35 | 33 | 31 | 31 | 31 | 31 | 30 | 28 | 28 | 12 | 12 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSkye Bioscience, Inc. (SKYE) — SEC Financial Statements & Analysis
Skye Bioscience, Inc. (SKYE) is a pharmaceutical preparations company, incorporated in NV. Skye Bioscience, Inc. trades on Nasdaq as: SKYE. Skye Bioscience, Inc. (SKYE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Skye Bioscience, Inc. carries a market cap of $220.06M, a P/E ratio of -4.36x, a P/B ratio of -442.51x, an enterprise value of $212.14M, and an EV/EBITDA multiple of -4.14x. On profitability, it posts a Return on Equity (ROE) of -233.87%, a Return on Assets (ROA) of -159.80%, and a Return on Invested Capital (ROIC) of -847.48%. Per share, it reports EPS of $-1.27, diluted EPS of $-1.27, free cash flow per share of $-0.98, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 19.16% year-over-year and EPS growth of 19.06% year-over-year. On the balance sheet, it maintains a current ratio of 0.95x, a quick ratio of 0.91x, working capital of $-572.22K, a debt-to-equity ratio of -23.19x, a debt ratio of 1.05, an interest coverage ratio of -7467.01x, free cash flow of $-38.81M (TTM), and net debt of $-7.93M. Figures sourced from SEC EDGAR.
- Market Cap
- $220.06M
- P/E TTM
- -4.36x
- EPS TTM
- $-1.27
- P/B TTM
- -442.51x
- ROE TTM
- -233.87%
- ROA TTM
- -159.80%
- Debt To Equity
- -23.19x
- Free Cash Flow TTM
- $-38.81M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Skye Bioscience, Inc. in?
Skye Bioscience, Inc. (SKYE) operates in the Pharmaceutical Preparations industry.
What exchange does SKYE trade on?
Skye Bioscience, Inc. (SKYE) trades on the Nasdaq.
Where is Skye Bioscience, Inc. incorporated?
Skye Bioscience, Inc. is incorporated in NV.
When was Skye Bioscience, Inc. (SKYE)'s most recent SEC filing?
Skye Bioscience, Inc. (SKYE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is SKYE's market cap?
Skye Bioscience, Inc. (SKYE) has a market capitalization of $220.06M as of 2026-06-30.
What is SKYE's EPS (earnings per share)?
Skye Bioscience, Inc. (SKYE)'s trailing twelve month EPS is $-1.27 as of 2026-06-30.
What is SKYE's ROE (return on equity)?
Skye Bioscience, Inc. (SKYE)'s trailing twelve month Return on Equity (ROE) is -233.87% as of 2026-06-30.
What is SKYE's ROA (return on assets)?
Skye Bioscience, Inc. (SKYE)'s trailing twelve month Return on Assets (ROA) is -159.80% as of 2026-06-30.
What is SKYE's ROIC (return on invested capital)?
Skye Bioscience, Inc. (SKYE)'s trailing twelve month Return on Invested Capital (ROIC) is -847.48% as of 2026-03-31.
What is SKYE's EV/EBITDA?
Skye Bioscience, Inc. (SKYE)'s trailing twelve month EV/EBITDA is -4.14x as of 2026-06-30.